Drug intelligence / Profile preview

ANP-330

Development stage: Preclinical
Lead developer: AlphaNavi Pharma
Modality: Small Molecules

Overview

ANP-330 is an early-stage therapeutic candidate being developed by AlphaNavi Pharma. While specific details regarding its molecular target and mechanism of action have not been publicly disclosed in detail, AlphaNavi Pharma focuses on the development of novel treatments for neurological and pain-related disorders, particularly targeting voltage-gated sodium channels such as Nav1.7 and Nav1.8. The compound appears in the company's internal development pipeline, though it has not yet progressed to advanced clinical trials as of the latest available reports.

Targets

SCN11A (NaV1.9)SCN10A (Sodium channel protein type X alpha subunit)SCN9A (Sodium channel protein type 9 subunit alpha)

Beyond the preview

Go deeper on ANP-330.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANP-330.

Explore the full profile